CSCHF yields 334.34% · PFE yields 6.20%● Live data
📍 CSCHF pulled ahead of the other in Year 1
Combined, CSCHF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSCHF + PFE for your $10,000?
China Renaissance Holdings Limited, an investment holding company, engages in investment banking and investment management businesses in Mainland China, Hong Kong, and the United States. It operates through Investment Banking, Investment Management, CR Securities, and Others segments. The Investment Banking segment offers financial advisory, and merger and acquisition advisory services; equity underwriting, sales, trading, brokerage, and research services; and structured financing services, which include exploring and developing non-equity financing services for new-economy firms. The Investment Management segment provides fund and asset management services for individual and institutional clients, as well as manages investment in funds. The CR Securities segment offers investment banking and asset management services. The Others provides wealth management services for high-net-worth individuals and other high net worth groups, as well as invests in and manages funds. The company serves startup and high-growth China-based companies, institutional secondary equity investors, and high net-worth individuals. China Renaissance Holdings Limited was founded in 2005 and is based in Beijing, China.
Full CSCHF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.